Basel, Switzerland-February 12, 2018-The Children’s Emergency Hospital "Louis Turcanu" (Spitalul Clinic de Urgenta pentru Copii „Louis Èurcanu”), in TimiÈoara, is the first hospital in Clinerion’s PRS network which specializes in pediatric care, opening up PRS to more expert research in the field. The "Louis Turcanu" hospital is the leading pediatric healthcare facility in Western Romania. Founded in 1903, it offers a variety of professional activities covering the full range of pediatric specialties. It has more than 500 beds and 8 principal investigators running more than 20 clinical studies per year. By joining Clinerion’s PRS platform, the "Louis Turcanu" hospital will benefit from improved access to leading-edge sponsored clinical trials run by international pharmaceutical companies and contract research organizations. The hospital’s investigators will reap huge time savings during site evaluation and when screening for eligible patients for studies. Their patients will gain early access to innovative medication and more options for treatments. They will also benefit from PRS’ ability to query their own patient database with complex criteria via a simple web interface without compromising patient privacy. “Our hospital has a long history of leadership in children’s health and we continue to contribute to the development of pediatric medicine by running studies for clinical research. PRS offers us exposure to more research which is innovative and international in scale,” says Dr. Adam Ovidiu, Manager of Louis Turcanu. “The beauty of Clinerion’s network is that we are able to propose trial sites around the world and with a plethora of specializations to sponsors. We are thrilled to add the Children’s Emergency Hospital "Louis Turcanu" and its expert pediatric clinicians to PRS,” says Ulf Claesson, CEO of Clinerion. About Clinerion Clinerion enables early patient access to innovative treatments through solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's PRS accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-assisted protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion's solutions comply with international patient privacy and data security regulations. Clinerion website: www.clinerion.com Clinerion’s PRS: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.